Use the search to find what you are looking for




28 Jul 2017

An editorial in this week’s Lancet Oncology is worth reading before we get too carried away, without evidence, of what immunotherapy might do for CUP patients. The concluding paragraph begins: ‘While heralding an enticing treatment opportunity, it is essential to bear in mind that the current generation of immunotherapies merely extends life expectancy for a small proportion of patients.’

17 Jul 2017

Pathology is critical to an accurate diagnosis of cancer – and for getting the best possible clues to aid treatment from the tissue of a patient where a site-specific diagnosis remains elusive. There are very few pathologists with expertise in CUP so it is good news – if not overdue news –  that The Royal College of Pathologists have drafted aRead more

10 Jul 2017

There is an interesting article in the business section of the Sunday Telegraph of 9 July 2017 ‘Welcome to the genomic era and its new gold rush’. The thrust is absolutely in line with the CUP Foundation’s wish list! Last week Dame Sally Davies, the chief medical officer, challenged the NHS and biotech companies to make genome sequencing standard withinRead more

04 Jul 2017

The report today that the Chief Medical Officer is throwing her weight behind genomic testing for cancer patients is encouraging. This is the report in the Daily Mail: ‘Genetic tests should be offered to millions of patients with cancer and other rare diseases, according to the chief medical officer. Dame Sally Davies said these would enable doctors to diagnose illnessesRead more

01 Jun 2017

The charity is 10 years old. To mark this, the Director has written a paper looking at the last ten years of CUP: the past, the current ‘state of play’, and a peek into the future. His thesis is that ‘the future is already here but it is not evenly distributed’.

26 May 2017

Molecular profiling to determine the tissue of origin of a patient’s CUP is not routinely undertaken in the UK – yet it is often a helpful aid to achieving an accurate diagnosis to allow focused treatment with confidence. The NHS need to be convinced of the cost/benefits of molecular profiling for CUP patients. A Canadian study has investigated the cost-effectiveness ofRead more

19 May 2017

We are an apolitical charity but on the realistic grounds that the Conservatives are most likely to regain power at the General Election it is interesting to note their manifesto commitment to: ‘continuing to support research into the diagnosis and treatment of rare cancers and other diseases, including Genomics England’s work in decoding 100,000 genomes’. What does it mean beyondRead more

12 Apr 2017

NICE have decided not to review the CUP Guideline having been advised of advances in immunohistochemistry markers and molecular profiling since the guideline was developed. The decision is shown here and, more interestingly, the evidence on which the decision was made is shown here. The recommendations from the review question are: Immunohistochemistry Use a panel of antibodies comprising cytokeratin 7 (CK7),Read more

15 Mar 2017

The abstract from a recent paper in Internal Medicine Journal makes for very interesting, if scary, reading: ‘Perceptions of Cancer of Unknown Primary Site – A National Survey of Australian Medical Oncologists: Australian Medical Oncologist CUP survey’ (Christos S Karapetis et al, Jan 2017).  The authors include Penny Schofield of our Advisory Board. The researchers invited all members of the Medical OncologyRead more

19 Feb 2017

In 2015 Jo’s friends director was invited to join an international group to begin to identify the big problems that a massive research grant (£20M) might encourage cancer scientists to try and solve. This is an exciting and novel approach to speed-up the search for cancer solutions outside the cumbersome, bureaucratic and slow research processes that characterize cancer research inRead more